StockCIK 1714899
Denali Therapeutics Inc. (DNLI): Insider Trades and Fund Holdings
In the past 12 months, Denali Therapeutics Inc. insiders reported 0 open-market purchases worth $0 and 4 sales worth $435K; 2 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$435KSold by insiders, 12 months
0Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 9, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 9 | Peter Scott ChinChief Medical Officer | ▼ SELL | $37K |
| Sep 4 | Nancy ThornberryDirector | ▼ SELL10b5-1 | $262K |
| Sep 3 | Alexander O. SchuthSecretary | ▼ SELL10b5-1 | $65K |
| Aug 13 | Alexander O. SchuthSecretary | ▼ SELL | $72K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Peter Scott Chin | Chief Medical Officer | 0 | $0 | 1 | $37K |
| Nancy Thornberry | Director | 0 | $0 | 1 | $262K |
| Alexander O. Schuth | Secretary | 0 | $0 | 2 | $137K |
ADVERTISEMENT
320 × 100 ad slot
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →